Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Ibex Technologies Inc. (V:IBT)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for IBT within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 22, 2024 16:30 ET
IBEX Reports Results for the Second Quarter and Six Months Ended January 31, 2024
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2024. “We were pleased to see revenues continue to increase as Q2 revenues were up...
Read full article
Mar 14, 2024 04:14 ET
IBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per Share
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) announces that it has filed an addendum to its management proxy circular dated February 23, 2024 for the annual and special meeting of shareholders to be held in Montreal, Québec...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.09
--
--
Price to Sales - TTM
4.49
2.67
3.46
Price to Book - most recent quarter
2.46
2.57
2.02
Price to Cash Flow per share - TTM
7.77
6.21
9.70
Price to Free Cash Flow per share - TTM
34.22
20.97
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20241,6150
Feb 15, 20247,4360
Jan 15, 20242,444-4,741
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.'s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA's) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.

See business summary

 

Twitter

Search (past week) for $IBT.CA IBT.V

  • No tweets found